MedTrace Logo

Effects of IAP-EOGBSD on Maternal Vaginal Microbiome, Offspring's Gut Microbiome and Metabolites.

NCT05738473 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 492

Last updated 2023-02-22

No results posted yet for this study

Summary

In view of the current status of prevention and research on GBS disease in mothers and infants at home and abroad, this project intends to explore the characteristics of vaginal microbiota of GBS-colonized pregnant women in southern China, the impact of IAP prevention of GBS-EOD on vaginal flora, and the effect of IAP prevention of GBS-EOD on intestinal flora and immune production in offspring, so as to improve the ability to prevent and treat GBS-related diseases in mothers and infants and promote maternal and infant health.

Conditions

  • Microbiome, Human

Interventions

DRUG

antibiotic

For pregnant women with GBS colonization, antibiotics are used to prevent infection

Sponsors & Collaborators

  • Zhongshan Bo Ai Hospital

    collaborator OTHER

  • Zhujiang Hospital

    lead OTHER

Principal Investigators

  • Qian Wang · Southern Medical University, China

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-23
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05738473 on ClinicalTrials.gov